🔬🧬 Oncology Updates: Keytruda Approval, Nanobody Breakthrough, Radioligand Deal and More
From Canada’s regulatory greenlight for KEYTRUDA to Saudi Arabia’s potential fast-track for Multikine and promising data in lung, bladder, and prostate cancer—this week’s roundup highlights the clinical momentum shaping oncology’s next frontier.
đź’ˇ Key Highlights This Week:
âś… KEYTRUDA approved in Canada as neoadjuvant and adjuvant therapy for PD-L1+ resectable head and neck cancer, showing 30% reduction in event-free survival risk in Phase III KEYNOTE-689
âś… CEL-SCI files for Breakthrough Designation in Saudi Arabia for Multikine; global Phase 3 data shows 5-year survival improved from 45% to 73%
🧬 Akeso doses first patient in Phase III Ivonescimab trial for limited-stage SCLC; PD-1/VEGF bispecific enters late-stage testing
🧪 KRIBB develops nanobody drug targeting lung adenocarcinoma; preclinical data show 70–90% tumor shrinkage via CD155-targeted doxorubicin delivery
🇺🇸 Mabwell launches U.S. trial for Bulumtatug Fuvedotin in resistant TNBC patients; no biomarker screening required
🤝 Pilatus and Roche begin HCC trial of PLT012 + Tecentriq to reprogram “”cold”” tumors by blocking CD36 lipid uptake
🧠Leads Biolabs completes enrollment in global Opamtistomig trial for EP-NEC; world’s first registrational monotherapy study in this aggressive indication
đźš» KEYTRUDA + Padcev improves event-free and overall survival in MIBC patients ineligible for cisplatin in Phase III KEYNOTE-905
⚡ Halda’s HLD-0915 receives FDA Fast Track Designation for mCRPC; RIPTAC platform targets AR and effector proteins
đź”— Primo Biotech and AnBogen announce collaboration on peptide-based radioligand therapy for solid tumors across Asia-Pacific
🎯 Whether you’re following bispecifics, antibody-drug conjugates, or radioligand innovations—this episode delivers the breakthroughs shaping precision oncology worldwide.
📢 Stay Ahead in Oncology Research!
âś… Like, share, and subscribe for weekly updates on oncology breakthroughs and cancer immunotherapy
#Oncology #CancerResearch #Immunotherapy #ClinicalTrials #KEYTRUDA #ADC #Nanobody #RadioligandTherapy #LucidQuest #HeadAndNeckCancer #LungCancer #BladderCancer #ProstateCancer #TNBC #SCLC #HCC #EPNEC #mCRPC #SolidTumors #BiotechNews #HealthcareUpdates #OncologyBreakthroughs #PharmaInnovation